-
New testing and treatments have led to a transformative moment for Alzheimer’s disease, a fact that was on full display during a recent Davos Alzheimer’s Collaborative meeting. The Davos Alzheimer’s Collaborative, first launched in 2021, is “working on a global scale to address disparities in Alzheimer’s research” with a research cohort numbering one million people, […]
-
Blueprint sells Atlanta senior housing community Blueprint was contracted in the sale of a 37-unit assisted living and memory care community in a submarket of Atlanta, Georgia. According to a press release, Blueprint leveraged its experience in selling a similar portfolio in 2023, and advised the client to choose “ a repeat buyer with a […]
-
How Memory Care Operators Market Their Services in a New Digital Age
By Guest Contributor| February 28, 2024By: Sloane Airey Memory care providers are looking at new – and old – ways to market their services to prospective residents. Doing so is perhaps harder than ever before. Residents and their families are doing their research online more than before the pandemic. But that can be a double-edged sword. A recent series of […]
-
Researchers Use AI to Predict Alzheimer’s 7 Years Before Symptoms Appear
By Andrew Christman| February 27, 2024Researchers at the University of California San Francisco say they have found a new way to use artificial intelligence to spot indicators of Alzheimer’s up to seven years before symptoms appear. Researchers utilized a tool called Scalable Precision Medicine Oriented Knowledge Engine, or SPOKE, developed at UCSF “identify patterns and potential molecular targets for therapy.” […]
-
Survey Shows Low Satisfaction With New Alzheimer’s Drug Leqembi
By Andrew Christman| February 27, 2024Fewer than half of the neurologists surveyed in a new report are recommending Leqembi to patients. According to the new report from market research firm Spherix Global Insights, satisfaction in the drug is “relatively low” six months into its commercial launch, with an average satisfaction rate of the treatment 15% lower than “the typical rating […]
-
A debate has simmered in the world of Alzheimer’s research and treatment: Should the disease’s definition be expanded to older adults who have a higher risk of dementia, but currently lack memory problems? The answer to that question, at least according to certain researchers, is yes. As noted in a recent Los Angeles Times article, […]
-
How Garden Spot Used ‘Sonic Treatment’ to Improve Memory Care Operations
By Andrew Christman| February 22, 2024What an older adult with dementia hears throughout the night may help promote better sleep and bring about a variety of other wellness benefits. That’s according to the findings of a study conducted by Garden Spot Communities in collaboration with the Center for Health Design and Composure, an audio technology company dedicated to serving senior […]
-
Declining Skeletal Muscle Health May Be Early Indicator of Alzheimer’s
By Andrew Christman| February 22, 2024Declining skeletal muscle health might be an early indicator of Alzheimer’s disease. That’s according to researchers from Virginia Tech’s College of Agriculture and Life Sciences, who have linked declining skeletal muscle health in Alzheimer’s with impaired peripheral nerve function. The study was conducted in collaboration with the University of Arkansas and funded by the National […]
-
How Breaking Down Care Bottlenecks Could Improve Dementia Treatment
By Austin Montgomery| February 14, 2024Primary care provider engagement could be key in increasing the pace and scope of treatment of early-stage Alzheimer’s disease, according to a new report. By getting primary care physicians to diagnose and evaluate patients for dementia-related treatment could make the greatest impact on cutting specialist visit wait times and boost the number of those treated […]
-
Biogen CEO: Demand for Alzheimer’s Drug Leqembi Increasing
By Tim Regan| February 14, 2024A growing number of patients are using Leqembi, a drug used to treat Alzheimer’s, according to maker Biogen (Nasdaq: BIIB). The company cited Alzheimer’s Network registries and noted there were about 3,800 patients on the drug as of last week, representing a 56% increase to that total from December, management noted during Biogen’s fourth-quarter earnings […]